

Correlated Error in Reviews of Immune Dysregulation

Abstract

In chronic pulmonary immune-dysregulation research, a convincing output can still be invalid when agreement between reviews counted as experimental replication. A bounded review of the literature is used to formulate, rather than claim to complete, an evaluation. The primary literature contributes a bounded result: the publication synthesizes low-grade inflammation, tissue remodeling, tolerance, and disease-specific pulmonary contexts. Repeated narratives can arise because reviews cite the same influential paper. Their agreement is then a property of the literature network as well as of the underlying phenomenon. Trace claims back to primary observations and identify overlapping evidence paths. Report where apparent consensus rests on few independent studies. The proposed comparison concerns review overlap, critique models, shared references; it would test whether the specific failure scenario is detected without erasing legitimate uncertainty. An integrated account should preserve the distinction between disease-specific biofilm and immune observations and any stronger downstream decision.

A bounded analytical problem

The scientific difficulty is a mismatch between what is observed and what is claimed. Chronic pulmonary immune-dysregulation research makes that mismatch concrete through review overlap and shared references. Consider the possibility of agreement between reviews counted as experimental replication. This is a proposed stress scenario, not an observed event reported by the cited studies. Its purpose is to expose which evidence contract would be violated even if the final output looked plausible. For disease-specific biofilm and immune observations, the relevant claim must identify its population or artifact class, its time window, and the action it is supposed to support. A failure at any of these levels may persist even after a local technical improvement. The analysis therefore treats published methods as bounded evidence and asks how their limitations interact with this particular decision. An operational analogy is useful only if it keeps those limitations visible.

Repeated narratives can arise because reviews cite the same influential paper. Their agreement is then a property of the literature network as well as of the underlying phenomenon. Synthesis must look beneath the review layer. In this article, the relevant contrast is review overlap, critique models, shared references. The proposed counterexample of agreement between reviews counted as experimental replication puts that contrast under pressure. Trace claims back to primary observations and identify overlapping evidence paths. Report where apparent consensus rests on few independent studies. A favorable finding would show that the intended interpretation of shared references remains defensible when review overlap is perturbed under the specified conditions. An unfavorable finding should narrow the claim rather than be discarded as an inconvenient case.

A reviewer of correlated error in reviews of immune dysregulation should be able to recover a claim before judging an output. The illustrative case is agreement between reviews counted as experimental replication. The input record should retain enough information to decide which part of that scenario violates the intended contract. That includes the original source type, measurement or artifact status, and the reason the proposed interpretation exceeds its support. The evaluator would compare the system's response with a qualified judgment made without seeing that response. Disagreement should be classified rather than erased by rewriting the prompt. Synthesis must look beneath the review layer. A useful negative result would show that the interface cannot preserve this distinction under realistic use; a useful positive result would

demonstrate preservation on independent cases rather than merely on the example used to develop the rule. The primary source remains relevant through its particular contribution: It treats biofilms as active modifiers of host immune states rather than merely a count of persisting organisms. That contribution should be retained even if the integrated workflow fails. Conversely, successful integration would not remove the source's limitations or turn a proposed extension into an already observed result. This asymmetric interpretation protects both the literature and the user from an unjustified all-or-nothing verdict.

Contrasts among the cited approaches

The relevant question in *Biofilm-Mediated Immune Dysregulation in Chronic Pulmonary Diseases: Mechanisms and Clinical Implications* is how persistent biofilms can dysregulate immunity in chronic pulmonary conditions (Xiao Yu et al. 2026a). Its methodological basis is a review of biofilm interactions with innate and adaptive responses, including pattern recognition, extracellular traps, macrophage polarization, and T-cell differentiation. The accessible evidence is specific: the publication synthesizes low-grade inflammation, tissue remodeling, tolerance, and disease-specific pulmonary contexts. It treats biofilms as active modifiers of host immune states rather than merely a count of persisting organisms. Mechanisms vary across COPD, bronchiectasis, asthma, and other contexts; proposed combined antibiofilm/immunomodulatory strategies are not proven universal treatments. Reading the work through source dependence changes the evaluation question: the issue is whether review overlap supports the intended interpretation of shared references, rather than whether the reported method is impressive in its original task.

The relevant question in *Immune Niches in Brain Tumors: Glial-Immune Cell Interactions and Spatial Microdomains* is how spatial glial-immune interactions organize permissive and suppressive microdomains within brain tumors (Qian Guo et al. 2026). Its methodological basis is a review of astrocytes, microglia, oligodendrocyte-lineage cells, T cells, and myeloid cells across spatial tumor niches. The accessible evidence is specific: the abstract integrates cytokine, metabolic, hypoxic, and immunoediting mechanisms associated with immune suppression and exhaustion. It shifts attention from tumor-wide averages to interactions whose meaning depends on location and cell context. The review does not establish efficacy of a new intervention; co-location, state annotation, and functional interaction require different evidence. The contribution becomes relevant to source dependence when the workflow moves from review overlap to shared references. That transition is the review's proposed analytical focus, not a new result attributed to the source.

AutoCrit: A Meta-Reasoning Framework for Self-Critique and Iterative Error Correction in LLM Chains-of-Thought asks whether structured self-critique can interrupt error propagation in language-model reasoning chains (Yinghao. “AutoCrit: A Meta-Reasoning Framework for Self-Critique Sang 2025). Its methodological basis is a reasoning agent, critique agent, and execution monitor provide iterative stepwise feedback and correction. The accessible evidence is specific: the abstract describes GSM8K, CSQA2, and ALFWorld evaluations, reported improvements over chain-of-thought baselines, and a fixed-point analysis of the correction process. It organizes critique as a monitored reasoning process rather than a single request to reconsider an answer. Shared model biases can correlate critic and reasoner errors, while extra iterations increase cost; benchmark gains do not establish clinical factuality. This source enters the present review as a methodological comparison for evidence processing, not as evidence about disease biology, patient outcomes, or clinical efficacy. The transferable question is whether review overlap remains correctly interpreted after a computational choice involving shared references. Its task-specific validation cannot be borrowed to validate the clinical claim.

The sources should be compared through the roles they play, not merged into a single performance claim. *Biofilm-Mediated Immune Dysregulation in Chronic Pulmonary Diseases: Mechanisms and Clinical*

Implications addresses how persistent biofilms can dysregulate immunity in chronic pulmonary conditions (Xiao Yu et al. 2026a). By contrast, AutoCrit: A Meta-Reasoning Framework for Self-Critique and Iterative Error Correction in LLM Chains-of-Thought addresses whether structured self-critique can interrupt error propagation in language-model reasoning chains (Yinghao. “AutoCrit: A Meta-Reasoning Framework for Self-Critique Sang 2025). That difference matters for source dependence: the evidence concerning review overlap is not automatically evidence concerning shared references. A successful software operation, a plausible mechanistic account, and a validated outcome are different achievements. Their integration may improve traceability, but it cannot create an unmeasured link. A coherent review should identify where the sources complement one another and where their scopes remain incompatible. Here the proposed failure scenario is agreement between reviews counted as experimental replication. The analytical value of that scenario is that it can occur without requiring any cited paper to be wrong: an otherwise valid local finding can be misused at a later interface. Preventing that misuse requires evidence about the interface itself, not simply a larger collection of local results.

Evaluation obligations

Medical machine learning must fit data provenance, care pathways, and prospective evaluation (Rajkomar, Dean, and Kohane 2019). The clinical relevance of a model depends on how its output changes a care process. Development data can contain information that becomes available only after the intended decision. A review must identify that availability boundary before comparing algorithms. Prospective use also changes who is measured and who is treated, so evaluation of a frozen historical dataset cannot establish the entire future workflow. An implementation should expose this limitation to reviewers of disease-specific biofilm and immune observations. The result and its evidence qualification should remain recoverable even when the interface condenses them into a short report.

Responsible health AI connects prediction with workflow, monitoring, and patient impact (Wiens et al. 2019). The point at which a model reaches practice is not the end of evaluation. New populations, changing measurements, and feedback can alter failure modes. A responsible deployment needs a route for recognizing deterioration and a person authorized to respond. Monitoring should be linked to feasible corrective actions; an alert that cannot change the workflow provides accountability only in a very limited sense. For the comparison involving review overlap, critique models, shared references, the source supplies an analytical obligation. The review's proposed application remains a hypothesis, with the deliberately difficult scenario serving as a check on scope inflation.

Calibration separates discrimination from confidence used in clinical escalation (Guo et al. 2017). Discrimination and calibration deserve separate evaluation. A score can order cases well yet systematically overstate its certainty. Aggregate calibration can also hide local miscalibration near the threshold where action changes. An audit should retain predicted probabilities and observed outcomes rather than report only correct classifications, and it should evaluate calibration on data not reused to choose the correction. An implementation should expose this limitation to reviewers of disease-specific biofilm and immune observations. The result and its evidence qualification should remain recoverable even when the interface condenses them into a short report.

Uncertainty can deteriorate under the site and cohort shifts common in biomedicine (Ovadia et al. 2019). Uncertainty is most valuable when a system moves beyond familiar conditions, yet those conditions can also weaken its uncertainty estimates. A warning mechanism must therefore be evaluated under shift rather than assumed to generalize because it works on ordinary held-out data. Different shifts can affect ranking, calibration, and error concentration differently. No single in-distribution curve demonstrates protection against them all. The connection to correlated error in reviews of immune dysregulation is a constraint on

interpretation. It would be inappropriate to borrow the source's methodological authority as direct confirmation of the integrated domain claim.

Selective prediction formalizes abstention when evidence does not support action (Geifman and El-Yaniv 2017). Abstention creates a tradeoff between coverage and residual error. Comparing systems without matching coverage can make one look safer merely because it leaves more work unfinished. Deferred cases also consume human or computational resources. The evaluation should show the risk-coverage relation and account for the fate of excluded cases, rather than treating them as though they have ceased to matter. Within chronic pulmonary immune-dysregulation research, this distinction is relevant to source dependence. The proposed failure scenario is agreement between reviews counted as experimental replication; its evaluation must preserve the original source's methodological scope.

Feature attribution can guide audit but does not establish biological causality (Lundberg and Lee 2017). Attribution decomposes a model output according to a defined explanatory convention. That decomposition can reveal dependence on suspicious features without establishing why the outcome occurs in the world. Reference choices and feature dependence can affect interpretation. A useful audit should compare explanations with known model behavior and should not transform a feature contribution into a treatment or mechanism claim. Within chronic pulmonary immune-dysregulation research, this distinction is relevant to source dependence. The proposed failure scenario is agreement between reviews counted as experimental replication; its evaluation must preserve the original source's methodological scope.

Health-AI governance requires accountability, transparency, inclusion, and protection of autonomy (World Health Organization 2021). Health-AI governance concerns people affected by a system as well as the organization operating it. Transparency without a route to challenge an output is incomplete. Autonomy and inclusion require attention to who can obtain follow-up, who is represented in evaluation, and who bears false alarms. These obligations remain even when an assistance tool is described as advisory rather than decisive. This is methodological support for examining source dependence, not a claim that the source studied chronic pulmonary immune-dysregulation research. A separate application-specific test is required at the interface described in this review.

Replication and transparent workflows are prerequisites for reliable biomedical claims (National Academies 2019). Reproducing a calculation and independently replicating a finding are different achievements. Recoverable data and code allow one to inspect the first; independent observations and design choices inform the second. A review should avoid calling several reanalyses of one dataset separate replications. Clear reporting of analysis changes also makes a failed replication informative instead of allowing it to disappear as an implementation dispute. This is methodological support for examining source dependence, not a claim that the source studied chronic pulmonary immune-dysregulation research. A separate application-specific test is required at the interface described in this review.

FAIR principles support reusable cohorts, signals, and analysis metadata (Wilkinson et al. 2016). Reusable evidence needs more than a downloadable file. Identifiers, metadata, provenance, and meaningful access conditions help another researcher determine what an artifact contains and whether it can answer a new question. Reuse does not mean universal permission or universal scientific comparability. The information needed to judge those boundaries should travel with the artifact rather than remain in private workflow knowledge. This is methodological support for examining source dependence, not a claim that the source studied chronic pulmonary immune-dysregulation research. A separate application-specific test is required at the interface described in this review.

Causal inference requires a clearly specified intervention, time order, and exchangeability assumptions (Hernán and Robins 2020). A prediction can be accurate without identifying what an intervention would

change. A useful causal analysis begins by defining the hypothetical comparison, eligibility, and time zero. Its assumptions concern the process generating exposure and observation, not merely the flexibility of a fitted model. In this review, causal vocabulary is appropriate only when that comparison can be specified and defended. This is methodological support for examining source dependence, not a claim that the source studied chronic pulmonary immune-dysregulation research. A separate application-specific test is required at the interface described in this review.

Proposed validation strategy

To make correlated error in reviews of immune dysregulation empirically criticizable, the next study could proceed as follows. Trace claims back to primary observations and identify overlapping evidence paths. Report where apparent consensus rests on few independent studies. These procedures are proposed, not completed. The case set would include the scenario of agreement between reviews counted as experimental replication, with its validity judged independently of the system's response. The relevant comparison axes are review overlap, critique models, shared references.

An evidence-role protocol would map each publication to its underlying observations and its permissible conclusions. The test cases would include reviews of the same primary study, correspondence without new data, and observations at incompatible scales. Reviewers would identify scope inflation before seeing the automated summary. An integrated system would be credited for preserving a missing link, not rewarded for making every source fit one complete narrative.

For the immune review, proposed mechanisms should be tested in their stated compartments and disease settings. Spatial association, state annotation, and intervention response would be judged separately. A useful result could expose a missing bridge in the integrated account. It would not need to confirm every part of the preferred narrative to improve scientific understanding.

Remaining uncertainty

The cited sources still have design-specific limits even where their abstracts and methods are accessible. This review is a bounded conceptual synthesis rather than a systematic review with an exhaustive search protocol. It cannot establish the effectiveness of the proposed integrated workflow. Its specific contribution is to articulate how source dependence changes the interpretation of review overlap, critique models, shared references. Technical sources support computational comparisons only; they do not validate biological mechanisms or patient benefit. Reviews and correspondence retain their publication roles and are not counted as new experiments. Proposed stress cases are illustrative, not observed failures attributed to the papers. Future work should therefore test the weakest inference described here, preserve contrary results, and disclose the cost of checking rather than treating additional automation as intrinsically beneficial.

Conclusion

Review overlap deserves to remain distinguishable from shared references. That distinction is the central safeguard identified by this review. Trace claims back to primary observations and identify overlapping evidence paths. Report where apparent consensus rests on few independent studies. The primary source remains bounded by its own design: Mechanisms vary across COPD, bronchiectasis, asthma, and other contexts; proposed combined antibiofilm/immunomodulatory strategies are not proven universal treatments. A trustworthy workflow would preserve the evidence source, the assumptions of the transition, and the right to stop when support is insufficient. The proposed evaluation agenda gives those obligations observable tests while withholding claims of completed validation.

References

1. Yu, Xiao, et al. "Biofilm-Mediated Immune Dysregulation in Chronic Pulmonary Diseases: Mechanisms and Clinical Implications." *Frontiers in Microbiology*, vol. 16, 2026, <https://doi.org/10.3389/fmicb.2025.1736384>.
2. Guo, Qian, et al. "Immune Niches in Brain Tumors: Glial-Immune Cell Interactions and Spatial Microdomains." *Acta Neuropathologica Communications*, vol. 14, 2026, <https://doi.org/10.1186/s40478-026-02373-0>.
3. Sang, Yinghao. "AutoCrit: A Meta-Reasoning Framework for Self-Critique and Iterative Error Correction in LLM Chains-of-Thought." *2025 6th International Conference on Machine Learning and Computer Application (ICMLCA)*, IEEE, 2025, pp. 1177-80, <https://doi.org/10.1109/icmlca66850.2025.11336788>.
4. Rajkomar, Alvin, Jeffrey Dean, and Isaac Kohane. "Machine Learning in Medicine." *New England Journal of Medicine*, vol. 380, 2019, pp. 1347-58.
5. Wiens, Jenna, et al. "Do No Harm: A Roadmap for Responsible Machine Learning for Health Care." *Nature Medicine*, vol. 25, 2019, pp. 1337-40.
6. Guo, Chuan, et al. "On Calibration of Modern Neural Networks." *Proceedings of the 34th International Conference on Machine Learning*, 2017, pp. 1321-30.
7. Ovadia, Yaniv, et al. "Can You Trust Your Model's Uncertainty? Evaluating Predictive Uncertainty under Dataset Shift." *Advances in Neural Information Processing Systems*, vol. 32, 2019.
8. Geifman, Yonatan, and Ran El-Yaniv. "Selective Classification for Deep Neural Networks." *Advances in Neural Information Processing Systems*, vol. 30, 2017.
9. Lundberg, Scott M., and Su-In Lee. "A Unified Approach to Interpreting Model Predictions." *Advances in Neural Information Processing Systems*, vol. 30, 2017.
10. World Health Organization. *Ethics and Governance of Artificial Intelligence for Health*. World Health Organization, 2021.
11. National Academies of Sciences, Engineering, and Medicine. *Reproducibility and Replicability in Science*. National Academies Press, 2019.
12. Wilkinson, Mark D., et al. "The FAIR Guiding Principles for Scientific Data Management and Stewardship." *Scientific Data*, vol. 3, 2016, article 160018.
13. Hernán, Miguel A., and James M. Robins. *Causal Inference: What If*. Chapman & Hall/CRC, 2020.